Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,718 Mln
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
--
Debt to Equity
0
ROE
-0.33 %
ROCE
-33.19 %
Div. Yield
0 %
Book Value
12.72
EPS
-2.88
CFO
$-394.43 Mln
EBITDA
$-599.44 Mln
Net Profit
$-586.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Avidity Biosciences - ADR
| 6.05 | -7.39 | 3.94 | 22.92 | 22.76 | -- | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Avidity Biosciences - ADR
| 218.28 | -59.22 | -6.65 | -6.86 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's... product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Read more
Co-Founder & Chairman
Dr. Troy Edward Wilson J.D., Ph.D.
Co-Founder & Chairman
Dr. Troy Edward Wilson J.D., Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Avidity Biosciences Inc - ADR stood at $ 1,564 Mln as on 31-Dec-24
The share price of Avidity Biosciences Inc - ADR is $30.84 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Avidity Biosciences Inc - ADR has given a return of 22.76% in the last 3 years.
Avidity Biosciences Inc - ADR has a market capitalisation of $ 3,718 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Avidity Biosciences Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Avidity Biosciences Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Avidity Biosciences Inc - ADR.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
The CEO & director of Dr. Troy Edward Wilson J.D., Ph.D.. is Avidity Biosciences Inc - ADR, and CFO & Sr. VP is Dr. Troy Edward Wilson J.D., Ph.D..
There is no promoter pledging in Avidity Biosciences Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Avidity Biosciences Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-33.47
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-2957.71
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Avidity Biosciences Inc - ADR was $0 Mln.
$-0.09
(
